Companies / OSL

ONCOSIL MEDICAL LTD

ASX:OSLPharmaceuticals, Biotechnology & Life Sciences
30.9M shares on issueASX (delayed) · as of 28 July 2026$1.17price · delayed$37.2Mmarket cap · indicative
D
Dilution grade

Runway under 2 quarters; share count grew 136% in 24 months; 3 cash raises in 24 months

Cash runway1.9 quarters of funding
Share-count growth (24m)135.9%
Raise cadence (24m)3 cash raises
Options & rights overhang1.1% of sharesconsolidation-adjusted
In-the-money supply0.0% of sharesconsolidation-adjusted
Pending proposed issuesnone

ONCOSIL MEDICAL LTD's ordinary share count grew 135.9% between July 2024 and July 2026 to 31M shares; this figure is adjusted for a consolidation (approximately 1-for-289) completed in June 2025. The company raised capital three times in the 24-month window for total disclosed proceeds of A$21.5M, most recently a Placement and Non-Renounceable Entitlement Offer in January 2026 that raised A$8.0M. Options and rights could convert into 331,580 new shares, equal to 1.1% of the current share count, with none in the money and the nearest expiry in October 2026; the option figures are consolidation-adjusted. At the March 2026 quarter the company reported A$5.5M in cash, about 1.9 quarters of cover. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
1.1%
Max option dilution
0.0%
ITM option dilution
1
Raises · last 12 months
1.9 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Adjusted for the 1-for-289 consolidation (5 June 2025). Latest count 30.9M per ASX (delayed) (28 July 2026).
17.7M22.6M27.4MDec 24Sept 25July 261-for-289 consolidationCash raise · 29 Jan 2026Cash raise · 9 July 2025

Cash runway

1.9 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$5.5M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
23 July 20262A · quoted issueOSL : ORDINARY FULLY PAID30.9MAppendix 2A
17 July 20262A · quoted issueOSL : ORDINARY FULLY PAID30.9MAppendix 2A
27 May 20263G · unquotedOSL : ORDINARY FULLY PAID30.7MAppendix 3G
27 May 20262A · quoted issueOSL : ORDINARY FULLY PAID30.9MAppendix 2A
17 Mar 20262A · quoted issueOSL : ORDINARY FULLY PAID23.6MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

3 cash raises in the last 24 months · 1 in the last 12 months

$8.0M
Placement and Non-Renounceable Entitlement Offer
29 Jan 2026 COMPLETE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

consolidation-adjusted Figures rebased for the share consolidation in the last 24 months.

1.1%
Total overhang · of current shares
0.0%
In the money · at current price
332k
Potential new shares
Oct 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
17 Mar 2026Thomas DuthyOther51k51k—3Y notice
17 Mar 2026Nigel LangeOther103k74k—3Y notice
17 Mar 2026Lelde SmitsOther44k44k—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

23 July 2026New Independent Study Confirms OncoSil Dose Flexibility
23 July 2026Application for quotation of securities - OSL
19 July 2026OncoSil Medical Receives Saudi Arabia FDA Approval
17 July 2026Application for quotation of securities - OSL
14 July 2026Investor Presentation
13 July 2026OSPREY Registry Abstract Accepted for EANM 2026 Congress
12 July 2026$POncoSil Medical Completes Manufacturing Validation
5 July 2026TRIPP-FFX Results Presented at ESMO GI 2026
2 July 2026$POncoSil Medical Files for FDA Approval
1 July 2026$POncoSil Selected for Major European Pancreatic Cancer Study
29 June 2026TRIPP-FFX Abstract Published on ESMO GI 2026 Website
29 June 2026Notice under ASX Listing Rule 3.10A
11 June 2026Publication verifies OncoSil strong localisation in pancreas
11 June 2026OncoSil Medical Launches Investor Hub
11 June 2026Change in substantial shareholding from AEF
9 June 2026TRIPP FFX accepted for oral presentation at ESMO GI 2026
8 June 2026US FDA HDE and TRIPP-FFX Study Presentation
8 June 2026$POncoSil progresses HDE with US FDA
8 June 2026$PTRIPP-FFX Clinical Trial Meets Co-Primary Endpoints
3 June 2026$PTrading Halt

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.